Cargando…
1971. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects
BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection and hospitalization in infants. Prophylaxis for RSV infection is only recommended for the highest risk infants, leaving the majority of infants unprotected. MK-1654 is a fully human monoclonal...
Autores principales: | Aliprantis, Antonios, Wolford, Dennis, Caro, Luzelena, Maas, Brian, Ma, Hua, Vora, Kalpit, Geng, Dong, Railkar, Radha, Lee, Andrew, Sterling, Laura, Lai, Eseng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254819/ http://dx.doi.org/10.1093/ofid/ofy210.1627 |
Ejemplares similares
-
1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
por: Maas, Brian, et al.
Publicado: (2018) -
998. Forward and Reverse Translational Approaches to Predict Efficacy of the Neutralizing Respiratory Syncytial Virus (RSV) Antibody MK-1654
por: Maas, Brian M, et al.
Publicado: (2021) -
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults
por: Orito, Yuji, et al.
Publicado: (2022) -
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
por: Maas, Brian M., et al.
Publicado: (2021) -
Curious Case of Hermaphroditism in 1654
Publicado: (1867)